EP2184057A1 - Arzneipastille mit langsamer Freisetzung des Wirkstoffs - Google Patents
Arzneipastille mit langsamer Freisetzung des Wirkstoffs Download PDFInfo
- Publication number
- EP2184057A1 EP2184057A1 EP10154760A EP10154760A EP2184057A1 EP 2184057 A1 EP2184057 A1 EP 2184057A1 EP 10154760 A EP10154760 A EP 10154760A EP 10154760 A EP10154760 A EP 10154760A EP 2184057 A1 EP2184057 A1 EP 2184057A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pellet
- matrix agent
- pastille
- gum
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 5
- 239000013543 active substance Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 claims abstract description 26
- 235000000346 sugar Nutrition 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 235000010603 pastilles Nutrition 0.000 claims abstract description 11
- 238000004090 dissolution Methods 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000008188 pellet Substances 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 15
- 210000000214 mouth Anatomy 0.000 claims description 15
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 12
- 239000000905 isomalt Substances 0.000 claims description 12
- 235000010439 isomalt Nutrition 0.000 claims description 12
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 238000010411 cooking Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229960002715 nicotine Drugs 0.000 claims description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 108010011485 Aspartame Proteins 0.000 claims description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 235000010449 maltitol Nutrition 0.000 claims description 6
- 239000000845 maltitol Substances 0.000 claims description 6
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 6
- 229940035436 maltitol Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 241000416162 Astragalus gummifer Species 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229920001615 Tragacanth Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 229920002678 cellulose Chemical class 0.000 claims description 4
- 239000001913 cellulose Chemical class 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 235000010494 karaya gum Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 241000206672 Gelidium Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920001100 Polydextrose Polymers 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- -1 carragaheen Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000013856 polydextrose Nutrition 0.000 claims description 3
- 239000001259 polydextrose Substances 0.000 claims description 3
- 229940035035 polydextrose Drugs 0.000 claims description 3
- 235000010408 potassium alginate Nutrition 0.000 claims description 3
- 239000000737 potassium alginate Substances 0.000 claims description 3
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000007937 lozenge Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229920000896 Ethulose Polymers 0.000 description 4
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 4
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960001698 nicotine polacrilex Drugs 0.000 description 3
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920003095 Methocel™ K15M Polymers 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229960004830 cetylpyridinium Drugs 0.000 description 2
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AQCRXZYYMOXFAN-UHFFFAOYSA-N 2-(1-methyl-2-pyrrolidinyl)-pyridine Chemical compound CN1CCCC1C1=CC=CC=N1 AQCRXZYYMOXFAN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000919496 Erysimum Species 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the invention relates to medicament sucking lozenges of solid consistency for dissolving in the oral cavity, comprising a matrix agent slowing the release of the active ingredient (s) in the buccopharyngeal sphere.
- the invention also relates to a process for manufacturing such a pellet.
- Medicinal lozenges are already known which are preparations based on sweetening substances, of solid consistency, intended to dissolve in the oral cavity.
- They are generally in various forms: spheres, cylinders, squares or any other polygonal shape.
- pellets also called cooked sugars
- auxiliary substances such as sweeteners, antioxidants, dyes, flavors, and the active ingredient (s).
- the active ingredient (s) are added to the mass in a mixer as well as the auxiliary substances.
- the mass thus prepared is kneaded on a suitable cold surface, then rolled and spun, to then be pressed or cut into pellets to the desired shape.
- the current medicinal pellets of cooked sugar dissolve very quickly in the mouth, between 5 and 10 minutes maximum, thus releasing too quickly the active ingredient (s) that they contain and which are immediately swallowed and absorbed at the level of the tract. digestive.
- the present invention provides novel medicinal pellets of cooked sugar which make it possible to overcome this disadvantage of the prior art.
- the invention relates, according to a first aspect, to a medicinal lozenge for sucking cooked sugar, of solid consistency, intended to dissolve in the oral cavity, comprising at least one active principle, the tablet further comprising at least one matrix agent to slow down the release of the active ingredient (s) which then remain in prolonged contact with the buccopharyngeal sphere.
- the matrix agent is an agent capable of slowing the dissolution of the cooked sugar in the mouth.
- the matrix agent also confers on the pellet an increased, durable resistance even in contact with the saliva so that the patient can not crunch the pellet and swallow pieces thereof.
- the dissolution time in the oral cavity of the pellet is at least 15 minutes, and typically 25 to 35 minutes, preferably 30 minutes.
- the matrix agent is typically chosen from the group consisting of non-cellulosic polysaccharides, cellulose derivatives, acrylic acid polymers, fatty substances, polyvinylpyrrolidone, these substances being used alone or as a mixture and representing 1 to 10% by weight of the pellet, typically 1 to 5%.
- the matrix agent is chosen from the group consisting of: guar gum, locust bean gum, sodium and potassium alginate, agar-agar, carragaheen, gum arabic, gum sterculia , gum tragacanth.
- the matrix agent is selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose.
- the acrylic acid polymer is a carbomer or a polymethacrylate, a copolymer of vinyl acetate.
- the fatty substance is selected from the group consisting of waxes, gelucires, glyceryl behenate, glyceryl palmitostearate.
- the matrix agent is polyvinylpyrrolidone.
- the tablet further comprises a major sugar excipient, or diluent, selected from sucrose, fructose, lactose, sorbitol, mannitol, lactitol, glucose, maltitol, isomalt, polydextrose, maltodextrins, used alone or in mixture representing 80 to 99% by weight of the pellet.
- a major sugar excipient selected from sucrose, fructose, lactose, sorbitol, mannitol, lactitol, glucose, maltitol, isomalt, polydextrose, maltodextrins, used alone or in mixture representing 80 to 99% by weight of the pellet.
- the tablet further comprises at least one auxiliary substance chosen from sweeteners, antioxidants, dyes and flavors.
- the invention relates to a tablet comprising as active ingredient nicotine.
- the tablet comprises isomalt, methocel (hydroxypropylcellulose), nicotine and a sweetening agent with a high sweetening power, especially aspartame.
- the matrix agent makes it possible to slow the dissolution of the cooked sugar in the mouth and at the same time the release of the active ingredient (s) at the site of action.
- the matrix agent confers on the cooked sugar pellet a significant resistance, durable even in contact with saliva, greater than that usually obtained on this type of preparation, so that it becomes impossible for the patient to chew on this lozenge and swallow the pieces.
- This complementary phenomenon is particularly favorable to the prolonged effect sought on the site of action, since the patient is obliged to let the pellet melt in the mouth until it is completely dissolved.
- the dissolving time in the oral cavity, obtained with this new form of cooked sugar pellets, can reach 30 minutes. This time can be modulated according to the choice of the sweetening agent (s) and the matrix agent (s).
- sweet diluent substances or excipient forming the basis of the preparation, which can be: sucrose, fructose, lactose, sorbitol, Mannitol, Lactitol, glucose, maltitol, Isomalt, Polydextrose, Maltodextrins ....
- Non-cellulosic polysaccharides that may be used include: guar gum, locust bean gum, sodium and potassium alginate, agar-agar, carragaheen, gum arabic, gum sterculia, gum tragacanth, xanthan gum, gum tragacanth, gum karaya.
- the substances constituting the matrix agent can be used alone or as a mixture. Their choices, their concentrations will depend on the sweetening substance (s) used, the active ingredient (s) retained and their activity, the desired dissolution time in the mouth and the texture of the cooked sugar.
- the major sugar excipient, or diluent is chosen from the aforementioned sugar substances used alone or in combination, again as above, depending on the desired result.
- Auxiliary substances are those usually used: sweeteners, antioxidants, dyes, flavors ....
- the manufacturing method according to the invention comprises four steps: a boiling step, a cooking step, a mixing step, a step of manufacturing the cooked sugar lozenges.
- the manufacturing process is in line with current pharmaceutical requirements.
- the active ingredient may be for example: nicotine, chlorhexidine digluconate, tetracaine, cetylpiridinium, plant extract.
- the matrix agent may be incorporated either during the boiling step or during the cooking step, or during mixing.
- the choice of the step of incorporation of the matrix agent will depend on the final characteristics of the desired cooked sugar pellets.
- the pellets thus obtained are very different from other galenic forms such as tablets which may contain some of the non-cellulosic polysaccharides and cellulose derivatives mentioned above.
- Amylin hydrochloride 2,000 mg Cetylpyridinium hydrochloride 1,000 mg polyvinylpyrrolidone 100,000 mg Sucrose 1577,000 mg Glucose 820,000 mg Aroma QS Dye QS Water QS
- Dextromethorphan hydrobromide 20,000 mg Citric acid 37,000 mg polymethyl 50,000 mg Sucrose 1,255,000 mg Glucose 1 111,000 mg Aroma QS Water QS
- the tablet of Examples 8 and 9 comprises 2.1303 g of nicotine.
- the manufacture of these pellets is carried out hot.
- the matrix agent is incorporated in the sweetening base at a temperature of the order of 70 to 95 ° C (boiling step), preferably at 90 ° C.
- the assembly is then heated to about 130 ° C at the time of cooking.
- the nicotine is then added (mixing step) in the mass at a temperature of the order of 110 to 130 ° C, preferably 120 ° C.
- Nicotine Polacrilex is a C 10 H 14 N 2 nicotine complex with an ion exchange resin (catioresin carboxylate); this complex has the formula: C 10 H 14 N 2 (C 18 H 22 O 4 ) n
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- General Preparation And Processing Of Foods (AREA)
- Road Signs Or Road Markings (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Confectionery (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10182581A EP2269588A1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer Freisetzung des Wirkstoffs |
CY20161100300T CY1117370T1 (el) | 2001-04-25 | 2016-04-12 | Φαρμακευτικη παστιλια με βραδεια απελευθερωσης του δραστικου παραγοντα |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0105554A FR2823974B1 (fr) | 2001-04-25 | 2001-04-25 | Pastille medicamenteuse a liberation lente du principe actif |
EP02726276A EP1383484B1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer freisetzung des wirkstoffs |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02726276.5 Division | 2002-04-25 | ||
EP02726276A Division EP1383484B1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer freisetzung des wirkstoffs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10182581A Division-Into EP2269588A1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer Freisetzung des Wirkstoffs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2184057A1 true EP2184057A1 (de) | 2010-05-12 |
EP2184057B1 EP2184057B1 (de) | 2016-01-13 |
Family
ID=8862665
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10154760.2A Expired - Lifetime EP2184057B1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer Freisetzung des Wirkstoffs |
EP10182581A Withdrawn EP2269588A1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer Freisetzung des Wirkstoffs |
EP02726276A Expired - Lifetime EP1383484B1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer freisetzung des wirkstoffs |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10182581A Withdrawn EP2269588A1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer Freisetzung des Wirkstoffs |
EP02726276A Expired - Lifetime EP1383484B1 (de) | 2001-04-25 | 2002-04-25 | Arzneipastille mit langsamer freisetzung des wirkstoffs |
Country Status (12)
Country | Link |
---|---|
US (1) | US8545870B2 (de) |
EP (3) | EP2184057B1 (de) |
AT (1) | ATE465721T1 (de) |
BR (1) | BRPI0209221B8 (de) |
CA (1) | CA2445200C (de) |
CY (1) | CY1117370T1 (de) |
DE (1) | DE60236149D1 (de) |
DK (2) | DK2184057T3 (de) |
ES (2) | ES2565464T3 (de) |
FR (1) | FR2823974B1 (de) |
PT (1) | PT1383484E (de) |
WO (1) | WO2002085334A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052851A1 (en) * | 2002-09-16 | 2004-03-18 | Graff Allan H. | Modified release oral dosage form |
SE0302947D0 (sv) | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
UA112974C2 (uk) * | 2010-09-16 | 2016-11-25 | Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид | Нікотиновмісна композиція (варіанти) |
FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
US20130206150A1 (en) * | 2012-02-10 | 2013-08-15 | R.J. Reynolds Tobacco Company | Multi-layer smokeless tobacco composition |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
US9044035B2 (en) | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
FR2993778B1 (fr) | 2012-07-30 | 2016-06-17 | Pf Medicament | Pastilles a cinetiques multiples de liberation de principes actifs |
US10244786B2 (en) | 2013-10-03 | 2019-04-02 | Altria Client Services Llc | Tobacco lozenge |
US10105320B2 (en) | 2013-10-03 | 2018-10-23 | Altria Client Services | Soluble fiber lozenge |
US9999243B2 (en) | 2013-10-03 | 2018-06-19 | Altria Client Services Llc | Exhausted tobacco lozenge |
US11779045B2 (en) | 2013-10-03 | 2023-10-10 | Altria Client Services Llc | Dissolvable-chewable exhausted-tobacco tablet |
US9351936B2 (en) * | 2013-10-03 | 2016-05-31 | Altria Client Services Llc | Nicotine lozenge |
US9375033B2 (en) | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
CN108684938A (zh) * | 2018-04-16 | 2018-10-23 | 广州智特奇生物科技股份有限公司 | 一种植物精油包被液、微胶囊植物精油及其制备方法 |
US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
CA3160750A1 (en) | 2019-12-09 | 2021-06-17 | Anthony Richard Gerardi | Oral product comprising a cannabinoid |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
US11883527B2 (en) | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1144915A (en) * | 1966-11-24 | 1969-03-12 | Armour Pharma | Improvements in or relating to pastille formulations |
GB2178658A (en) * | 1985-07-26 | 1987-02-18 | Vincent Processes Limited | Sustained release tablets and a method of manufacture thereof |
WO1997042941A2 (en) * | 1996-05-13 | 1997-11-20 | Novartis Consumer Health S.A. | Buccal delivery system |
EP0839524A1 (de) * | 1996-10-29 | 1998-05-06 | Montefarmaco S.p.A. | Pharmazeutische Zusammensetzungen zur oralen Verwendung enthaltend Desinfektionsmittel und Mukoadhäsiva |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
US5200194A (en) * | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
DE19536394A1 (de) * | 1995-09-29 | 1997-04-03 | Basf Ag | Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze |
DE19606968C2 (de) * | 1996-02-24 | 1998-07-09 | Suedzucker Ag | Verwendung von 1,1-GPS in Hartkaramellen |
TW474824B (en) * | 1996-09-13 | 2002-02-01 | Basf Ag | The production of solid pharmaceutical forms |
US5942244A (en) * | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
US20040101543A1 (en) * | 2002-03-22 | 2004-05-27 | John Liu | Nicotine-containing oral dosage form |
-
2001
- 2001-04-25 FR FR0105554A patent/FR2823974B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-25 EP EP10154760.2A patent/EP2184057B1/de not_active Expired - Lifetime
- 2002-04-25 DK DK10154760.2T patent/DK2184057T3/en active
- 2002-04-25 DE DE60236149T patent/DE60236149D1/de not_active Expired - Lifetime
- 2002-04-25 CA CA2445200A patent/CA2445200C/fr not_active Expired - Lifetime
- 2002-04-25 AT AT02726276T patent/ATE465721T1/de active
- 2002-04-25 EP EP10182581A patent/EP2269588A1/de not_active Withdrawn
- 2002-04-25 EP EP02726276A patent/EP1383484B1/de not_active Expired - Lifetime
- 2002-04-25 WO PCT/FR2002/001421 patent/WO2002085334A1/fr not_active Application Discontinuation
- 2002-04-25 US US10/475,778 patent/US8545870B2/en active Active
- 2002-04-25 BR BRPI0209221A patent/BRPI0209221B8/pt not_active IP Right Cessation
- 2002-04-25 DK DK02726276.5T patent/DK1383484T3/da active
- 2002-04-25 ES ES10154760.2T patent/ES2565464T3/es not_active Expired - Lifetime
- 2002-04-25 PT PT02726276T patent/PT1383484E/pt unknown
- 2002-04-25 ES ES02726276T patent/ES2340761T3/es not_active Expired - Lifetime
-
2016
- 2016-04-12 CY CY20161100300T patent/CY1117370T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1144915A (en) * | 1966-11-24 | 1969-03-12 | Armour Pharma | Improvements in or relating to pastille formulations |
GB2178658A (en) * | 1985-07-26 | 1987-02-18 | Vincent Processes Limited | Sustained release tablets and a method of manufacture thereof |
WO1997042941A2 (en) * | 1996-05-13 | 1997-11-20 | Novartis Consumer Health S.A. | Buccal delivery system |
EP0839524A1 (de) * | 1996-10-29 | 1998-05-06 | Montefarmaco S.p.A. | Pharmazeutische Zusammensetzungen zur oralen Verwendung enthaltend Desinfektionsmittel und Mukoadhäsiva |
Also Published As
Publication number | Publication date |
---|---|
BRPI0209221B1 (pt) | 2018-03-13 |
US20060171994A1 (en) | 2006-08-03 |
WO2002085334A1 (fr) | 2002-10-31 |
CA2445200C (fr) | 2011-09-06 |
FR2823974A1 (fr) | 2002-10-31 |
EP1383484A1 (de) | 2004-01-28 |
PT1383484E (pt) | 2010-05-27 |
DK2184057T3 (en) | 2016-04-18 |
DK1383484T3 (da) | 2010-06-07 |
DE60236149D1 (de) | 2010-06-10 |
ATE465721T1 (de) | 2010-05-15 |
CA2445200A1 (fr) | 2002-10-31 |
ES2565464T3 (es) | 2016-04-04 |
ES2340761T3 (es) | 2010-06-09 |
BR0209221A (pt) | 2004-06-15 |
EP2184057B1 (de) | 2016-01-13 |
US8545870B2 (en) | 2013-10-01 |
BRPI0209221B8 (pt) | 2021-07-27 |
EP2269588A1 (de) | 2011-01-05 |
CY1117370T1 (el) | 2017-04-26 |
EP1383484B1 (de) | 2010-04-28 |
FR2823974B1 (fr) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2184057B1 (de) | Arzneipastille mit langsamer Freisetzung des Wirkstoffs | |
EP1467715B1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
US6455053B1 (en) | Quickly soluble solid preparations | |
US6187336B1 (en) | Process for producing a solid which is rapidly soluble in the oral cavity | |
AU2003267268B2 (en) | Modified release oral dosage form | |
JP4439499B2 (ja) | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 | |
EP0814789B2 (de) | Arzneimittel enthaltend monoaminooxidase-b-hemmer | |
BRPI0709382A2 (pt) | forma de dosagem sólida contendo um agente ativo de sabor mascarado | |
CA2017360A1 (fr) | Forme pharmaceutique poreuse et sa preparation | |
EP1465593B1 (de) | In der mundhöhle dispergierbare feste pharmazeutische form | |
EP2131823B1 (de) | Schnell zerfallende einschichtige folie zur oralen verabreichung von wirkstoffen | |
US20230121000A1 (en) | Solid dosage form for transmucosal drug delivery | |
US20110028480A1 (en) | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors | |
KR20090130580A (ko) | 제제학적으로 안정한 츄어블 연질캡슐 조성물 | |
EP2879663B1 (de) | Lutschtabletten mit mehrfacher freisetzungskinetik für wirkstoffe | |
JPH0426618A (ja) | トローチ剤 | |
RU2729659C1 (ru) | Лекарственная форма для высвобождения дротаверина в полости рта | |
FR2997856A1 (fr) | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate | |
CN118178358B (zh) | 一种地喹氯铵口腔贴膜制剂及其制备方法 | |
CN117838668A (zh) | 一种盐酸多奈哌齐口腔速溶膜剂及其制备工艺 | |
FR2666227A1 (fr) | Composition therapeutique notamment pour le traitement des affections de la cavite buccale. | |
CA3149554A1 (fr) | Comprime orodispersible d'opioide a faible dosage et son procede de preparation | |
FR2618678A1 (fr) | Composition pharmaceutique pour le traitement des inflammations de la cavite buccale | |
JP2013047284A (ja) | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1383484 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DUPINAY, PIERRE Inventor name: CAPON, CHRISTINE Inventor name: TORRES, ROBERT |
|
17P | Request for examination filed |
Effective date: 20101103 |
|
17Q | First examination report despatched |
Effective date: 20101210 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DUPINAY, PIERRE Inventor name: TORRES, ROBERT Inventor name: CAPON, CHRISTINE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/465 20060101ALI20120319BHEP Ipc: A61K 9/22 20060101AFI20120319BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150721 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1383484 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 770028 Country of ref document: AT Kind code of ref document: T Effective date: 20160215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60247743 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI AND CIE SA, CH |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2565464 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160404 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20160412 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20160412 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 770028 Country of ref document: AT Kind code of ref document: T Effective date: 20160113 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20160400665 Country of ref document: GR Effective date: 20160601 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60247743 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20161014 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160113 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20210316 Year of fee payment: 20 Ref country code: LU Payment date: 20210315 Year of fee payment: 20 Ref country code: NL Payment date: 20210312 Year of fee payment: 20 Ref country code: FI Payment date: 20210322 Year of fee payment: 20 Ref country code: IE Payment date: 20210322 Year of fee payment: 20 Ref country code: GR Payment date: 20210318 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20210329 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210408 Year of fee payment: 20 Ref country code: CY Payment date: 20210318 Year of fee payment: 20 Ref country code: IT Payment date: 20210413 Year of fee payment: 20 Ref country code: FR Payment date: 20210429 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20210414 Year of fee payment: 20 Ref country code: TR Payment date: 20210414 Year of fee payment: 20 Ref country code: AT Payment date: 20210322 Year of fee payment: 20 Ref country code: BE Payment date: 20210421 Year of fee payment: 20 Ref country code: GB Payment date: 20210415 Year of fee payment: 20 Ref country code: ES Payment date: 20210506 Year of fee payment: 20 Ref country code: CH Payment date: 20210426 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60247743 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20220424 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20220425 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20220425 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20220424 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 770028 Country of ref document: AT Kind code of ref document: T Effective date: 20220425 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220504 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220425 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220424 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220426 |